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LETTERS TO THE EDITORCORONARY SINUS REDUCER
STENT
To the Editor:
I read with great interest the article
by Guenter Weigel and colleagues.1 I
want to commend the authors for their
great effort to understand the cascade
of molecular events leading to neovas-
cularization in coronary sinus inter-
ventions. However, I would like to
add some comments.
The term ‘‘Beck procedure’’ alone
is a nonspecific term inasmuch as Dr
Claude Beck has described two types
of coronary sinus interventions.2-4
The first one, the Beck I procedure,
consisted of narrowing the coronary
sinus to a diameter of 3 mm, abrading
both the epicardium and inner pericar-
dium, spilling of powdered asbestos
and 5% aqueous trichloracetic acid
on the epicardium, and placement of
mediastinal fat over the treated epicar-
dium. The second, the Beck II proce-
dure, consisted of a vascular graft
between the descending aorta and the
coronary sinus followed by operative
constriction of the coronary sinus
ostium a few weeks later. However,
both of these procedures have very
little in common with pressure-
controlled intermittent coronary sinus
occlusion (PICSO), which was studied
by the authors.
PICSO has more in common with
the coronary sinus reducer stent
(CSRS) that was developed as an alter-
native treatment for patients with re-
fractory angina pectoris.5 The CSRS
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duces the coronary sinus diameter to
3 mm. It is introduced into the cor-
onary sinus via the venous system,
using a percutaneous approach. Fif-
teen patients with severe angina pec-
toris have already been successfully
treated by this technology.5
Personally, I had the opportunity to
invent the Neovasc Reducer in the
mid-1990s and to lead its initial de-
velopment team until 2002. The pri-
mary idea was to increase a stenotic
coronary artery perfusion pressure
by limiting its outflow. In other
words, if we cannot increase the cor-
onary input, let’s limit or decrease its
output; instead of manipulating the
coronary arteries, let’s treat the coro-
nary veins—the upside-down strat-
egy. However, even our first study
in nonischemic pigs revealed that
8 to 12 weeks of coronary sinus
narrowing ended up with macro-
scopic epicardial new blood ves-
sels—neovascularization. This was
also seen intramyocardially. On those
days, the cascade leading from coro-
nary sinus narrowing to new macro-
scopic epicardial and intramyocardial
blood vessels was not clear enough
and some explanations other than
neovascularization were suggested.
The current study by Guenter Weigel
and colleagues sheds some light on
this subject by favoring the neoangio-
genesis explanation that is triggered
by some kind of increased coronary
sinus pressure.
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SINGLE-STAGE VERSUS
2-STAGE REPAIR OF
COARCTATION OF THE AORTA
WITH VENTRICULAR SEPTAL
DEFECT
To the Editor:
We read with interest the article by
Walters and colleagues1 on single- ver-
sus 2-stage repair of coarctation (CoA)
with ventricular septal defect (VSD)
and congratulate the authors for excel-
lent outcomes in patients undergoing
single-stage repair of both lesions.
However, we would be very cautious
in adopting this strategy just because it
has been shown to be technically feasi-
ble and equally effective in the authors’
experience. As the authors have ac-
knowledged themselves, the study pop-
ulation comprises patients spread over
a long time frame. We may understand
here that when the surgical protocols
were developing at the authors’ institu-
tion, the authors may have elected for
a 2-stage approach over a 1-stage ap-
proach. As the protocols may have
evolved, they were able to make this
shift in strategy. However, what promp-
ted them to perform only CoA repair
combined with arch augmentation on
cardiopulmonary bypass (CPB) and
circulatory arrest leaving the VSD
open in 3 of their patients is unclear.
An important factor to be consid-
ered in developing countries is the
morbidity and the costs of the proce-
dure the patients undergo.2 Group 1
patients had a prolonged course in008
